Time is on their side

The U.S. takeover target cleaned house a bit by unloading its genetictesting arm. The more Genzyme can do to fix itself up, the more likely it can squeeze the French Sanofi to sweeten its $18.5 bln bid. Biotechs, once in play, almost always sell. A higher bid seems likely.